Stock Performance of Big Pharma's Biotech Partners
Executive Summary
One advantage of signing partnerships, theoretically, is the benefit to a biotech's share price. But does a deal with one or another Big Pharma itself make a difference?
You may also be interested in...
Genus Triumphs Over FDA In Barium Sulfate Product Classification Suit
The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.
Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Tech Transfer Roundup: BridgeBio’s R&D Efforts Span New Seven New Agreements
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.